Breztri Aerosphere Inhalation

Regulated Product — Business License Required

B2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.

Product photography not yet supplied — this space will show official packaging imagery once provided by the business.

Product Overview

Breztri Aerosphere Inhalation is a metered-dose inhaler combining three medicines — budesonide (an inhaled corticosteroid), glycopyrronium (a long-acting antimuscarinic), and formoterol (a long-acting beta-agonist). It is prescribed for the maintenance treatment of chronic obstructive pulmonary disease (COPD) to help reduce coughing, chest tightness, and shortness of breath.

Active ingredients
Budesonide + Glycopyrronium + Formoterol fumarate
Dosage form
Metered-dose inhaler (aerosol)
Therapeutic class
ICS / LAMA / LABA triple therapy
Regulatory status
Prescription / regulated — confirmed per enquiry and destination market
Availability
Confirmed per enquiry

Product Information

The following description reflects information associated with budesonide, glycopyrronium, and formoterol and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.

Described Uses

  • Maintenance treatment of chronic obstructive pulmonary disease (COPD)
  • Described as reducing coughing, chest tightness, and shortness of breath
Note: SDO Pharma has not independently verified the manufacturer’s efficacy claims for this product and makes no additional medical or clinical claims beyond what is described here. We do not claim FDA, UAE, EU, or other specific regulatory approval for this product unless independently verified. This is a prescription / regulated-status product; patient dispensing is the responsibility of the licensed business customer, not SDO Pharma.

Described Dosage & Administration

  • Check the label; shake the inhaler before use
  • Breathe in through the mouth while pressing the inhaler once; hold the breath for about 10 seconds
  • Repeat for the number of puffs prescribed, then rinse the mouth with water and spit it out

Described Side Effects

Commonly described side effects include:

  • Dizziness
  • Vomiting
  • Stuffy nose
  • Oral thrush or throat irritation (reduced by rinsing the mouth after use)

Any severe, persistent, or unexpected reaction requires prompt medical attention.

Precautions

  • A maintenance (preventer) inhaler — not for the relief of a sudden breathing attack
  • Treatment should not be stopped abruptly even if symptoms improve
  • Smoking and alcohol should be avoided
  • Complete medical history should be shared with the prescriber; pregnancy or breastfeeding should be disclosed

This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.

B2B, Import & Export

B2B, Import & Export Enquiries

SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.

We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.

Product Enquiry

Request Product Information

Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.

Frequently Asked Questions

Per its labelling, it is a budesonide/glycopyrronium/formoterol inhaler for the maintenance treatment of COPD. SDO Pharma has not independently verified these claims.

No. It is described as a maintenance (preventer) therapy and is not intended to relieve a sudden breathing attack.

Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.

Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.

Explore More

Related Product Categories

SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.

View Products & Services